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Abstract
Background Loop diuretics are frequently prescribed to patients with heart failure and reduced ejection fraction (HFrEF) 
for the treatment of congestion; however, they might hamper uptitration of inhibitors of the renin–angiotensin system.
Methods Loop diuretic dose at baseline was recorded in 2338 patients with HFrEF enrolled in BIOSTAT-CHF, an inter-
national study of HF patients on loop diuretic therapy who were eligible for uptitration of angiotensin-converting enzyme 
inhibitors (ACEi)/mineralocorticoid receptor antagonists (MRA). The association between loop diuretic dose and uptitration 
of ACEi/MRA to percentage of target dose was adjusted for a previously published model for likelihood of uptitration and 
a propensity score.
Results Baseline median loop diuretic dose was 40 [40–100] mg of furosemide or equivalent. Higher doses of loop diuretics 
were associated with higher NYHA class and higher levels of NT-proBNP, more severe signs and symptoms of congestion, 
more frequent MRA use, and lower doses of ACEi reached at 3 and 9 months (all P < 0.01). After propensity adjustment, 
higher doses of loop diuretics remained significantly associated with poorer uptitration of ACEi (Beta per log doubling of 
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loop diuretic dose: − 1.66, P = 0.021), but not with uptitration of MRAs (P = 0.758). Higher doses of loop diuretics were 
independently associated with an increased risk of all-cause mortality or HF hospitalization [HR per doubling of loop diu-
retic dose: 1.06 (1.01–1.12), P = 0.021].
Conclusions Higher doses of loop diuretics limited uptitration of ACEi in patients with HFrEF and were associated with a 
higher risk of death and/or HF hospitalization, independent of their lower likelihood of uptitration and higher baseline risk.
Graphic abstract
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Abbreviations
ACEi  Angiotensin-converting enzyme 
inhibitor
ARB  Angiotensin receptor blocker
BIOSTAT-CHF  A systems BIOlogy Study to Tailored 
Treatment in Chronic Heart Failure
eGFR  Estimated glomerular filtration rate
HF  Heart failure
NT-proBNP  N-terminal pro blood natriuretic peptide
NYHA  New York Heart Association
MRA  Mineralocorticoid receptor antagonists
RAAS  Renin-angiotensin-aldosterone system
Introduction
In patients with heart failure, administration of loop diuret-
ics is the cornerstone of the treatment of signs and symp-
toms of congestion. While loop diuretics are almost ubiqui-
tously used in hospitalized heart failure, data from registries 
and randomized-controlled trials show that approximately 
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75–92% of patients with stable heart failure also use loop 
diuretics chronically [1–4]. Heart failure guidelines recom-
mend to use loop diuretics to reduce the signs and symptoms 
of congestion, and to use the lowest achievable dose to reach 
and maintain euvolemia [5]. If patients are asymptomatic, 
the use of a loop diuretic could be discontinued as loop diu-
retic downtitration or even withdrawal might be feasible in 
up to 60% of (selected) stable heart failure patients [6–8]. 
Such downtitration of loop diuretics might be important as 
overzealous use of diuretics can result in worsening of renal 
function, contraction of plasma volume, and lower blood 
pressures [4, 6]. Additionally, consequent hypovolaemia 
and hyponatraemia cause increased renin release through 
its effects on the macula densa and baroreceptors. These 
detrimental effects of inappropriate use of loop diuretics 
could also hamper the optimal uptitration of guideline rec-
ommended doses of angiotensin-converting enzyme inhibi-
tors (ACEi)/angiotensin receptor blockers (ARB), and min-
eralocorticoid receptor antagonists (MRA). Observational 
data illustrate that only a minority of patients are able to 
attain these target doses of neurohormonal blockers [9, 10]. 
Therefore, reasons for not uptitrating renin-angiotensin-
aldosterone system (RAAS) blockers to the recommended 
doses should be further explored. We hypothesize that 
higher doses of loop diuretics might hamper the uptitration 
of RAAS blockers. We, therefore, aimed to assess the effect 
of loop diuretic dosage on the ability to uptitrate patients 
to guideline recommended doses of ACEi/ARB and MRA, 
as well as to assess the association of loop diuretic dosage 
with outcome.
Methods
Study population
The study design of ‘A systems BIOlogy Study to Tailored 
Treatment in Chronic Heart Failure’ (BIOSTAT-CHF) has 
been described previously [11]. In brief, BIOSTAT-CHF 
was a multicentre, multinational, prospective observational 
study, in which 2516 patients with new-set or worsening 
signs and/or symptoms of heart failure from 11 European 
countries, who were on suboptimal guideline recom-
mended treatment (i.e.,  ≤ 50% of target doses of ACEi/
ARBs and beta-blockers), were enrolled. Physicians could 
enrol patients if they anticipated uptitration or initiation of 
ACEi/ARB and beta-blockers. Additionally, all patients in 
BIOSTAT-CHF had to be on a loop diuretic dose equal or 
more than 40 mg furosemide equivalents at inclusion (40 mg 
furosemide equals 20 mg torsemide or 1 mg bumetanide). 
Investigators were encouraged to optimize treatment of heart 
failure with ACEi/ARB and beta-blockers during the first 
3 months of the study, according to the doses indicated in the 
European Society of Cardiology Guidelines [12]. Patients 
with HFpEF (162 (6.4%) patients) defined as an ejection 
fraction > 45% were excluded from the current analyses, 
as uptitration of guideline directed medical therapy is not 
always required in these patients.
All patients provided written informed consent to par-
ticipate in the study and BIOSTAT-CHF was conducted in 
concordance with the Declaration of Helsinki. The study was 
approved by national and local ethics committees.
Study assessments
Both inpatients and outpatients were enrolled, and had a 
visit at baseline and after 9 months of follow-up. During 
the first 3 months, the treating physician was encouraged 
to uptitrated evidence-based therapies to the target doses 
presented in the 2008 and 2012 ESC heart failure guide-
lines [12, 13]. The subsequent 6 months were considered 
as a maintenance phase. Doses of evidence-based therapies 
were recorded at baseline, 3 months (only for ACEi/ARB 
and beta-blockers), and 9 months. Target doses of MRAs 
were based on the doses recommended in the heart failure 
guidelines, where for both spironolactone and eplerenone, 
a dose of 50 mg daily is considered target dose [5]. The 
dose of loop diuretics at baseline was available in 2338 of 
the 2354 patients (99%) with HFrEF enrolled in BIOSTAT-
CHF. Diuretics were calculated into furosemide equivalents 
(40 mg furosemide = 20 mg torsemide = 1 mg bumetanide). 
Downtitration of loop diuretics was defined as a decrease in 
loop diuretic dose from baseline to 9 months.
A previously defined congestion score was calculated 
as the sum of orthopnoea (0–1), JVP (0–1), and oedema 
depending on the severity (0–0.33–0.67–1), resulting in a 
maximum score of 3 points [14, 15]. The clinical congestion 
score at 9 months was available in 1167 (49.9%) patients. 
Sensitivity analyses were performed with a clinical conges-
tion score where oedema was scored 0–3 points, yielding a 
maximum score of 5 points.
Routine laboratory and other biomarker assessments 
were performed at baseline and 9 months, using previously 
described assays [16, 17]. Worsening renal function was 
defined as an increase in creatinine of > 0.3 mg/dL from 
baseline to 9 months.
The endpoints selected for these analyses were all-cause 
mortality and the combined endpoint of all-cause mortality 
or first occurrence of heart failure (HF) hospitalization. HF 
hospitalization was defined as hospitalization lasting longer 
than 1 day for which the primary reason was worsening of 
signs or symptoms of HF, requiring intravenous medications 
or an increased dose of oral diuretics.
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Statistical analyses
Baseline clinical variables and biomarkers were evaluated 
over quartiles of loop diuretic dosage. Frequency (percent-
age) was used to summarize categorical variables while 
normally distributed continuous variables were summarized 
with mean ± standard deviations (SD) and non-normally 
distributed continuous variables with median [interquartile 
range]. Trends over quartiles of loop diuretic dosage were 
statistically tested with Cochran–Armitage trend test, Jonck-
heere–Terpstra, or a linear regression model for categorical 
variables, non-normally distributed continuous variables, 
and normally distributed continuous variables, respectively. 
Univariable and multivariable linear regression analysis was 
performed with log-transformed loop diuretic dosage as a 
dependent variable. Transformations were checked using 
multifractional polynomials. Multivariable linear regression 
analyses, including all variables with P < 0.10 in univariable 
analysis, were constructed via backward elimination and 
validated using bootstrap re-sampling with 1000 replicates. 
The model was tested for collinearity and checked by plot-
ting residuals. Logistic regression was used to investigate the 
association between loop diuretic downtitration and clini-
cal variables as well as study the association between log-
transformed loop diuretic dosage and ACEi/ARB, or MRA 
use, and whether target dose was reached. The association 
between log-transformed loop diuretic dosage and percent-
age of target dose was studied using linear regression. A 
propensity score was determined using multivariable lin-
ear regression with loop diuretic dosage as the dependent 
variable, using the above described selection and backward 
elimination. This propensity score reflects the characteris-
tics associated with the prescription of higher doses of loop 
diuretics. The propensity score included age, hepatomegaly, 
diastolic blood pressure, previous heart failure hospitaliza-
tion, history of atrial fibrillation, history of COPD, urea, 
estimated glomerular filtration rate (eGFR), potassium, 
N-terminal pro blood natriuretic peptide (NT-proBNP), 
and plasma renin (Supplementary Table 1). Propensity score 
adjustment was used to reduce the effect of treatment selec-
tion bias in prescribing higher doses of loop diuretic dosage. 
The association between loop diuretic dose and uptitration 
of ACEi/ARB and MRAs, was adjusted for three multivari-
able models. First, we adjusted for age and sex. Second, we 
performed a multivariable adjustment for a previously pub-
lished model predicting lower doses of these medications in 
this cohort [18]. This model included sex, country of inclu-
sion, BMI, and eGFR. Finally, adjustment for a biological 
plausible model was performed, including age, sex, eGFR, 
NT-proBNP, and ACEi/ARB use at baseline. Cox propor-
tional hazard regression analysis was performed to examine 
associations with clinical outcomes. Log-transformed loop 
diuretic dosage was investigated per doubling. Multivariable 
models were adjusted for an outcome model specifically 
developed and validated in the BIOSTAT index and valida-
tion cohort [19]. A two-tailed P value < 0.05 was considered 
statistically significant. All analyses were performed using 
R: A Language and Environment for Statistical Comput-
ing, version 3.3.1 (R Foundation for Statistical Computing, 
Vienna, Austria).
Results
Median daily loop diuretic dose at baseline was 40 
[40–100] mg of furosemide or equivalent. Baseline charac-
teristics over quartiles of loop diuretic dose are presented 
in Table 1. Patients with higher loop diuretic doses were 
more frequently hospitalized, had a higher Body Mass 
Index (BMI), New York Heart Association (NYHA) func-
tional class, as well as more signs and symptoms of con-
gestion, lower blood pressure, and lower left-ventricular 
ejection fraction. Additionally, higher doses of loop diu-
retics were associated with poorer renal function, lower 
albumin, sodium, aldosterone to renin ratio, and higher 
NT-proBNP levels (all P < 0.001).
At 9 months, median loop diuretic dose was 40 [40–80] 
mg of furosemide or equivalent, with a median decline 
of 0 [− 40–0] mg. A total of 745 patients (37.2%) had a 
decrease, and 18.6% (373 patients had an increase in diu-
retic dose at 9 months. A significant number of patients 
displayed signs of congestion at 9  months: 18.1% of 
patients in the highest quartile of loop diuretic dosage 
had oedema above the knee, 12.3% had an elevated JVP, 
and 12.2% had orthopnoea (all P < 0.02, Supplementary 
Table 2).
Overall, patients with an increase in diuretic dose over 
9 months were comparable to patients with a decrease in 
diuretic dose (Supplementary Table 3), with no notable 
differences in baseline clinical presentation, laboratory 
values, or guideline recommended therapy over time. Pre-
dictors of loop diuretic downtitration were higher baseline 
loop diuretic dose, orthopnoea, lower plasma aldosterone 
levels, higher urea and eGFR at baseline, and no history of 
a cardiomyopathy, myocardial infarction, or diabetes mel-
litus (Table 2). Uptitration of ACEi/ARB or MRA was not 
independently associated with a decrease in loop diuretic 
dose at 9 months.
Loop diuretic dosage and ACEi/ARB and MRA 
uptitration
At baseline, there were no differences in dosage of ACEi/
ARB; yet, after 3 months of encouraged uptitration and 
an additional 6 month maintenance phase, patients with 
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Table 1  Baseline characteristics over quartiles of loop diuretic dose at baseline
Q1 Q2 Q3 Q4 P trend
N 1319 120 504 395
Loop diuretic dose 40 [40–40] 60 [50–60] 80 [80–120] 250 [160–300]
 min–max 1–40 45–60 70–125 130–600
Demographics
Sex [% Male(n)] 73.6 (971) 76.7 (92) 76 (383) 76.7 (303) 0.147
Age (years) 68.0 ± 12.2 65.9 ± 12.2 69.5 ± 11.8 69.0 ± 11.1 0.005
BMI (kg/m2) 27.6 ± 5.1 27.9 ± 4.8 28.2 ± 6 28.6 ± 6.1 0.002
NYHA class [%(n)]  < 0.001
 I 3 (39) 3.3 (4) 1.4 (7) 1 (4)
 II 41.8 (551) 31.7 (38) 27.6 (139) 23 (91)
 III 43.2 (570) 41.7 (50) 55.2 (278) 59.2 (234)
 IV 9.5 (125) 19.2 (23) 12.9 (65) 15.2 (60)
 Unknown 2.6 (34) 4.2 (5) 3.0 (15) 1.5 (6)
LVEF (%) 29.5 ± 7.7 30.7 ± 7.1 28.3 ± 8.2 27.9 ± 8.5  < 0.001
Clinical profile
Oedema [%(n)] 22.5 (239) 24 (24) 35 (151) 41.1 (146)  < 0.001
 Oedema above knee (%(n)) 5.4 (57) 6.0 (6) 5.4 (23) 11.8 (42)  < 0.001
Orthopnoea [%(n)] 29.3 (386) 37.5 (45) 42.7 (215) 40.6 (159)  < 0.001
Rales > 1/3 up lung fields [%(n)] 15.2 (87) 10.8 (7) 27.6 (82) 19.7 (46) 0.002
Jugular venous pressure [%(n)] 25.9 (216) 34.6 (28) 42 (146) 42.5 (119)  < 0.001
Hepatomegaly [%(n)]a 9.7 (127) 19.2 (23) 18.7 (94) 23.4 (92)  < 0.001
Third heart tone [%(n)] 10.6 (139) 10.8 (13) 9.8 (49) 9.4 (37) 0.463
Systolic blood pressure (mmHg) 126.5 ± 21.9 122.5 ± 20.4 122.3 ± 22.0 119.8 ± 20.4  < 0.001
Diastolic blood pressure (mmHg) 76.8 ± 12.9 74.1 ± 11.8 73.8 ± 14.3 71.6 ± 12.5  < 0.001
Heart rate (beats/min) 79.8 ± 20 79.0 ± 18.3 80.5 ± 18.7 79.6 ± 18 0.823
Hospitalization
Type of visit [%(n)]  < 0.001
 Scheduled outpatient 34.7 (458) 23.3 (28) 19.2 (97) 20.3 (80)
 Unscheduled outpatient 6.2 (82) 5 (6) 4.2 (21) 6.3 (25)
 Inpatient hospitalization 59.1 (779) 71.7 (86) 76.6 (386) 73.4 (290)
Reason for visit [%(n)] 0.213
 Worsening heart failure 49.5 (653) 49.2 (59) 59.5 (300) 69.6 (275)
 New-onset heart failure 29.6 (390) 28.3 (34) 28.4 (143) 13.9 (55)
 Other reason 20.9 (276) 22.5 (27) 12.1 (61) 16.5 (65)
Heart failure history
Years since first diagnosis 1.3 [0.2–6.1] 0.6 [0.3–7.8] 3.2 [0.5–9] 2.9 [0.4–6.6] 0.722
Ischemic heart disease [%(n)] 60.8 (709) 59.4 (63) 62 (286) 67 (240) 0.062
Previous HF hospitalization [%(n)] 28.7 (378) 32.5 (39) 35.1 (177) 42 (166)  < 0.001
Medical history
Hypertension [%(n)] 59.9 (790) 63.3 (76) 60.5 (305) 66.8 (264) 0.040
Atrial fibrillation [%(n)] 41.2 (543) 40 (48) 46.4 (234) 53.2 (210)  < 0.001
Diabetes mellitus [%(n)] 28.9 (381) 31.7 (38) 32.9 (166) 44.8 (177)  < 0.001
Laboratory
Creatinine (umol/L) 96.7 [79–117.3] 100 [79.6–123.8] 109 [91–142.8] 118 [92–158.1] 0.858
Urea (mmol/L) 9.4 [6.8–15.2] 15.4 [11.1–22.9] 11.9 [7.7–19.5] 14.4 [9.7–24.1]  < 0.001
eGFR (ml/min/1.73m2) 64.7 [49.1–82.8] 62.3 [47–81] 55.1 [40.7–72.5] 50.5 [34–69.7]  < 0.001
Sodium (mmol/L) 140 [137–142] 139 [137–142] 139 [136–141] 139 [136.8–141]  < 0.001
Potassium (mmol/L) 4.3 [4–4.6] 4.2 [3.9–4.5] 4.2 [3.9–4.5] 4.1 [3.8–4.5]  < 0.001
Albumin (g/L) 33 [28–39] 33 [28–37.5] 32 [26–37] 32 [26–37]  < 0.001
Aldosterone (pg/mL) 94 [46–189] 86.5 [33–166.8] 110 [44.1–231] 97 [44–233] 0.002
Renin (UI/mL) 65.2 [23.4–194.5] 124.1 [36.9–300.1] 127.1 [45.5–368.6] 175.7 [60.5–483.5]  < 0.001
Aldosterone-to-renin ratio 1.5 [0.4–4] 0.7 [0.2–2.4] 0.7 [0.2–2.1] 0.6 [0.1–1.7] 0.001
NT-proBNP (pg/mL) 2211.5 [974.2–4773.2] 2118.5 [1058–4323.2] 3315 [1526–7397.5] 3839.5 [1592–8886.5]  < 0.001
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higher doses of loop diuretics at baseline were less likely 
to use ACEi/ARB, and used lower doses both at 3 and 
9 months (Tables 3, and 4). In patients with higher doses 
of loop diuretics, symptoms, side-effects, and non-cardiac 
organ dysfunction were more frequently noted as the rea-
sons for not achieving target dose of ACEi/ARB (Table 3). 
After multivariable adjustment for the biological plausible 
model, as well as after multivariable adjustment for the 
previously published model for likelihood of uptitration, 
the association between higher loop diuretic dose and less 
use/dose of ACEI/ARB remained statistically significant 
(Table 4). 
Additionally, higher doses of loop diuretics at baseline 
were significantly associated with smaller increases in per-
centage of target doses of ACEi/ARB in univariable and 
multivariable analyses (Table 4). This association remained 
significant after propensity adjustment, i.e., higher doses of 
loop diuretics remained significantly associated with less 
uptitration both from baseline to 3 months (P = 0.021), and 
from baseline to 9 months (P = 0.013).
At baseline, patients in the highest quartile of loop diu-
retic dose at baseline were more likely to use MRAs and 
used higher doses (Table 3). At 9 months, there were, how-
ever, no significant differences in (change in) percentage of 
target doses of MRAs (Tables 3, 5).
There was no significant interaction between loop diuretic 
dosage and site of enrolment on successful uptitration, nor 
between worsening/new-onset heart failure or in-/outpatients 
and loop diuretic dosage. Additionally, there was no signifi-
cant association between loop diuretic doses and uptitration 
of beta-blockers after propensity adjustment (Supplementary 
Tables 4 and 5).
Loop diuretic dosage and congestion
As higher doses of loop diuretics are most frequently driven 
by signs and symptoms of congestion, we assessed the 
impact of congestion on loop diuretic dosing and (success-
ful) uptitration of ACEi/ARBs. Patients with a higher con-
gestion score at baseline were more likely to receive higher 
doses of loop diuretics at baseline as well as at 9 months, 
and used a significantly lower percentage of target dose of 
ACEI/ARB at baseline and at subsequent time points (Sup-
plementary Table 6). At 9 months, 846 (72.5%) patients 
were judged euvolemic based on the clinical congestion 
score of which 313 (37.0%) patients received uptitration of 
ACEi/ARB, and 305 (36.1%) patients were downtitrated in 
terms of loop diuretic dose. Of the 321 (27.5%) patients that 
displayed signs and symptoms of congestion at 9 months, 
106 (33.0%) patients received uptitration of ACEi/ARB, 
and 94 (29.3%) patients were downtitrated in terms of loop 
diuretic dose.
To elucidate the association between loop diuretic dos-
ing, congestion, and uptitration of ACEi/ARB, we divided 
patients based on a change in congestion score (decrease 
versus no change/increase) and the dose of loop diuretics at 
9 months (Supplementary Table 7). Patients with a decrease 
in congestion score but persistent high doses of loop diuret-
ics at 9 months were less likely to receive higher percent-
age of target doses of ACEi/ARB at 9 months (P = 0.034), 
and were less well uptitrated compared to patients with 
no change/increase in clinical congestion score and low/
medium doses of loop diuretics (Fig. 1), underscoring the 
relation between high doses of loop diuretics and inability to 
uptitrate ACEi/ARB. Sensitivity analyses with a congestion 
score attributing greater value to oedema yielded similar 
findings.
Loop diuretic dosage and outcomes
During a median follow-up of 21 [16–27] months, 602 
(25.7%) patients died, 567 (27.9%) patients were hospi-
talized for heart failure, and 939 (40.2%) patients experi-
enced the combined endpoint. Higher doses of loop diu-
retics were independently associated with an increased 
risk of the combined endpoint of all-cause mortality and 
heart failure hospitalization [HR per doubling of loop diu-
retic dosage: 1.06 (1.01–1.12), P = 0.021]. Kaplan–Meier 
curves for the combined endpoint for high (> 80  mg 
of furosemide or equivalent) versus low dose of loop 
Table 1  (continued)
BMI body mass index, eGFR estimated glomerular filtration rate, LVEF left-ventricular ejection fraction, NT-proBNP n terminal pro blood 
natriuretic peptide, NYHA New York Heart Association
a Based on physical examination
Table 2  Multivariable model downtitration of loop diuretics at 
9 months
eGFR estimated glomerular filtration rate
OR (CI) P value
Loop diuretic dose at baseline 3.45 (2.91–4.12)  < 0.001
Orthopnoea 1.50 (1.18–1.90)  < 0.001
History of cardiomyopathy 0.62 (0.48–0.79)  < 0.001
Myocardial infarction 0.67 (0.52–0.88) 0.002
Diabetes mellitus 0.65 (0.50–0.83)  < 0.001
Aldosterone 0.72 (0.57–0.91) 0.005
Urea 1.01 (100–1.02) 0.038
eGFR 1.01 (1.00–1.01) 0.008
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diuretics are shown in Fig. 2, illustrating a higher risk with 
a higher loop diuretic dose (log rank, P < 0.001). These 
results remain significant after multivariable adjustment 
(Supplementary Table 8). In patients with a high dose of 
loop diuretics (> 80 mg furosemide or equivalent), treat-
ment with > 50% of target dose of ACEi/ARB at 3 months 
was associated with a significantly lower risk of the 
combined endpoint (Fig. 3, log-rank P < 0.001, Supple-
mentary Table 8) compared to patients who were treated 
with ≤ 50% of the target dose. Even though patients with 
an increase in loop diuretic dose experienced numerically 
more events compared to patients with a decrease [182 
(48.8%) versus 234 (31.4%) events, P < 0.001], change in 
loop diuretic dose over time was not independently associ-
ated with an increased risk of the combined endpoint [HR 
per doubling of change in loop diuretic dose censored at 
9 months: 0.92 (0.38–2.20), P = 0.842].
Higher doses of loop diuretics are independently asso-
ciated with an increased risk of worsening renal function, 
even after adjustment for the propensity score and baseline 
creatinine [OR per doubling of loop diuretic dosage: 1.33 
(1.15–1.55), P < 0.001]. Change in loop diuretic dose was 
not associated with worsening renal function.
Discussion
This study provides novel and clinically relevant infor-
mation regarding the impact of loop diuretic dosage on 
uptitration of RAAS blockers in patients with heart failure 
Table 3  Doses of ACEi/ARB and MRA at baseline, 3 months, and 9 months over quartiles of loop diuretic doses at baseline
ACEi/ARB angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, MRA mineralocorticoid antagonists
a Defined as: percentage of target dose at 3 months minus percentages of target dose at baseline divided by percentage of target dose at baseline 
times 100
Q1 Q2 Q3 Q4 P trend
N 1319 120 504 395
Loop diuretic dose 40 [40–40] 60 [50–60] 80 [80–120] 250 [160–300]
ACE inhibitors or angiotensin receptor blockers
ACE inhibitors or angiotensin receptor blockers at baseline [%(n)] 75.4 (994) 66.7 (80) 70.6 (356) 71.9 (284) 0.045
 Target dose at baseline [%(n)] 17.7 (176) 21.2 (17) 18 (64) 20.8 (59) 0.328
 Percentage of target dose at baseline (%) 20 [0–50] 20 [0–50] 20 [0–50] 20 [0–50] 0.717
ACE inhibitors or angiotensin receptor blockers at 3 months [%(n)] 91.8 (1211) 85.8 (103) 84.9 (428) 82.5 (326)  < 0.001
 Target dose at 3 months [%(n)] 26.2 (317) 30.1 (31) 24.8 (106) 20.6 (67) 0.061
 Percentage of target dose at 3 months (%) 50 [20–80] 50 [20–100] 30 [10–60] 30 [10–50]  < 0.001
 Change in percentage of target dose from baseline to 3 months (%)a 0 [0–25] 0 [0–26.6] 0 [0–25] 0 [0–12.5]  < 0.001
ACE inhibitors or angiotensin receptor blockers at 9 months [%(n)] 90.8 (1197) 86.7 (104) 82.9 (418) 78 (308)  < 0.001
 Target dose at 9 months [%(n)] 29.2 (349) 30.8 (32) 25.6 (107) 21.4 (66) 0.006
 Percentage of target dose at 9 months (%) 50 [20–100] 50 [10–70] 20 [10–60] 20 [0–50]  < 0.001
 Change in percentage of target dose from baseline to 9 months (%)a 0 [0–25] 0 [0–50] 0 [0–25] 0 [0–12.5]  < 0.001
Reasons for not uptitrating ACE inhibitors [%(n)]  < 0.001
 Symptoms 7.2 (95) 5.0 (6) 9.3 (47) 10.4 (41)
 Side-effects 9.2 (122) 8.3 (10) 17.3 (87) 12.9 (51)
 Non-cardiac organ dysfunction 2.4 (32) 1.7 (2) 2.0 (10) 3.3 (13)
 Other 5.4 (71) 8.3 (10) 6.9 (35) 9.1 (36)
 Uptitrated according to guidelines 53.8 (709) 50.0 (60) 38.9 (196) 32.2 (127)
 Unknown 22.0 (290) 16.7 (32) 25.6 (129) 32.2 (127)
Mineralocorticoid antagonists
MRA at baseline [%(n)] 51.4 (678) 58.3 (70) 57.5 (290) 61.0 (241)  < 0.001
 Target dose at baseline (%(n)) 16.6 (106) 20.8 (11) 23.6 (63) 26.4 (56) 0.001
 Percentage of target dose at baseline (%) 50 [50–50] 50 [50–50] 50 [50–50] 50 [50–100] 0.001
MRA at 9 months [%(n)] 58.1 (653) 61.2 (60) 64.2 (250) 61.4 (173) 0.040
 Target dose at 9 months [%(n)] 16.0 (114) 12.5 (7) 16.7 (45) 22.8 (43) 0.071
 Percentage of target dose at 9 months [%(n)] 50 [25–50] 50 [18.8–50] 50 [25–50] 50 [25–50] 0.450
 Change in percentage dose from baseline to 9 months (%)a 0 [-100–0] 0 [-100–0] 0 [-76.2–0] 0 [-100–0] 0.861
 Clinical Research in Cardiology
1 3
and a reduced ejection fraction. First, in accordance with 
previous studies, higher doses of loop diuretics at base-
line are associated with more severe heart failure, more 
congestion, worsening renal function, and worse out-
comes. Second, there is a significant association between 
higher loop diuretic dosage and less successful uptitra-
tion of guideline recommended doses of ACEi/ARB, but 
not of MRA or beta-blockers. Third, our data suggest that 
the association between loop diuretics and uptitration of 
ACEi/ARB is only partly driven by factors influencing 
the prescription of higher doses of loop diuretics, as the 
association between uptitration of guideline recommended 
ACEi/ARB treatment and loop diuretic dosage remained 
significant even after propensity score adjustment. Fourth, 
in patients with an improvement in congestion yet persis-
tent high doses of loop diuretics, uptitration of ACEi/ARB 
was poorer. These data collectively support the recommen-
dation to dynamically adjust loop diuretic dose to facilitate 
uptitration of ACEi/ARBs.
Table 4  Loop diuretic dose and ACEi/ARB over time
ACEi/ARB angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, AF alkaline phosphatase, BMI body mass index, CI confidence 
interval, DBP diastolic blood pressure, eGFR estimated glomerular filtration rate, HR heart rate, NT-proBNP n terminal pro blood natriuretic 
peptide
a Adjusted for age and sex
b Adjusted for sex, country, BMI, AF, and eGFR
c Adjusted for log NT-proBNP, eGFR, age, sex, and ACE/ARB use at baseline
ACEi/ARB use at 
3 months
Target dose at 3 months Change in percentage of target 
dose from baseline to 3 months
Change in percentage of target 
dose from baseline to 9 months
OR (CI) P value OR (CI) P value Beta (CI) P value Beta (CI) P value
Log loop diuretic dose (per doubling)
 Univariable 0.78 (0.70–0.86)  < 0.001 0.88 (0.80–0.95) 0.003 − 2.81 (− 3.89 to 
1.72)
 < 0.001 − 4.04 (− 5.34 to 
2.72)
 < 0.001
 Multivariablea 0.78 (0.71–0.87)  < 0.001 0.88 (0.81–0.96) 0.004 − 2.70 (− 3.78 to 
1.62)
 < 0.001 − 3.87 (− 5.18 to 
2.57)
 < 0.001
 Multivariableb 0.88 (0.79–0.99) 0.028 0.85 (0.75–0.97) 0.013 − 1.93 (− 3.06 to 
0.81)
 < 0.001 − 2.73 (− 4.04 to 
1.42)
 < 0.001
 Multivariablec 0.88 (0.78–0.99) 0.031 0.83 (0.74–0.94) 0.004 − 2.34 (− 3.49 to 
1.20)
 < 0.001 − 3.43 (− 4.77 to 
2.09)
 < 0.001
 Propensity score 
adjusted
0.93 (0.82–1.05) 0.260 0.96 (0.85–1.09) 0.557 − 1.66 (− 3.07 to 
0.25)
0.021 − 2.09 (− 3.74 to 
0.44)
0.013
Table 5  Loop diuretic dose and MRA over time
AF alkaline phosphatase, BMI body mass index, CI confidence interval, DBP diastolic blood pressure, eGFR estimated glomerular filtration rate, 
HR heart rate, MRA mineralocorticoid receptor antagonist, NT-proBNP n terminal pro blood natriuretic peptide
a Adjusted for age, and sex
b Adjusted for sex, country, BMI, AF, and eGFR
c Adjusted for log NT-proBNP, eGFR, age, sex, and ACE/ARB use at baseline
MRA use at 9 months Target dose at 9 months Change in percent-
age of target dose 
from baseline to 
3 months
Change in percentage of target 
dose from baseline to 9 months
OR (CI) P value OR (CI) P value Beta (CI) P value Beta (CI) P value
Log loop diuretic dose (per doubling)
 Univariable 1.04 (0.96–1.13) 0.350 1.16 (1.01–1.33) 0.031 NA NA 0.53 (− 3.42 to 4.47) 0.794
 Multivariablea 1.05 (0.97–1.15) 0.249 1.18 (1.03–1.35) 0.017 NA NA 0.80 (− 3.15 to 4.75) 0.692
 Multivariableb 1.10 (0.93–1.32) 0.274 1.24 (1.03–1.50) 0.027 NA NA 4.24 (− 0.07 to 8.54) 0.054
 Multivariablec 1.09 (0.92–1.30) 0.333 1.15 (0.96–1.37) 0.121 NA NA 2.22 (− 2.00 to 6.45) 0.301
 Propensity score adjusted 1.05 (0.94–1.17) 0.370 1.14 (0.97–1.35) 0.117 NA NA 0.79 (− 4.27 to 5.86) 0.758
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Loop diuretics and guideline recommended 
treatment with RAAS blockers
Loop diuretics are the first-choice therapy for signs and 
symptoms of congestion in patients with heart failure, and 
are used in the majority of heart failure patients [1, 5]. No 
studies have shown that diuretics decrease mortality risk and 
several studies have even suggested an association between 
higher doses of loop diuretics and a higher risk of death, 
worsening renal function, and symptoms such as hypoten-
sion [4, 6]. Higher doses of loop diuretics might also influ-
ence the ability to uptitrate doses of RAAS blockers, which 
we sought to investigate in this study. In clinical practice, 
not all patients are treated with the recommended doses of 
neurohormonal blockers. BIOSTAT-CHF was designed to 
investigate the effects of 3 months of encouraged uptitration 
of ACEi/ARB and beta-blocker doses on clinical outcomes. 
In addition, we aimed to study patient profiles associated 
with impaired uptitration to ultimately move forward to 
a more personalized treatment approach in treating heart 
failure patients [11]. By design, this study provided a good 
context to assess the effect of loop diuretic dosage on suc-
cessful uptitration of guideline recommended treatment. 
It should, however, be noted that despite the encouraged 
uptitration, the number of patients receiving target doses at 
3 months did not differ greatly from data from registries [9, 
10]. In this study, we showed that patients with higher doses 
of loop diuretics showed signs of more severe heart fail-
ure and congestion. We also found a significant association 
between loop diuretic dosing and (percentage of) target dose 
of ACEi/ARB at 3 and 9 months. Interestingly, the asso-
ciation between higher doses of loop diuretics and smaller 
increases in ACEi/ARB doses over time remained significant 
after adjustment for the likelihood to be uptitrated, as well as 
after propensity score adjustment. The persistent significant 
association, even after propensity score adjustment, suggests 
that this association is independent of clinical characteristics 
leading to the prescription of higher doses of loop diuretics. 
These findings confirm our hypotheses that higher doses of 
loop diuretics hinder the uptitration of ACEI/ARB in these 
patients, and that the lower dose of ACEi/ARB attained in 
the high loop diuretic dose group may not merely be the 
reflection of sicker patients. Effects of higher loop diuretic 
doses on hypotension, worsening renal function, and elec-
trolyte imbalances might influence the physician’s decision 
in not uptitrating ACEi/ARB to guideline recommended 
doses. Interestingly, we did not observe a significant asso-
ciation between blood pressure and uptitration or downtitra-
tion of loop diuretics. Our data suggest that downtitration of 
loop diuretics to the lowest achievable dose (in euvolemic 
patients) as recommended by the heart failure guidelines 
could facilitate a better uptitration of ACEi/ARB.
Fig. 1  Median percentage of target dose of ACEi/ARB during follow-
up in patients with a decrease in congestion score subdivided based 
on loop diuretic dosage at 9 months. ACEi/ARB angiotensin-convert-
ing enzyme inhibitors/angiotensin receptor blockers, LD loop diuret-
ics
Fig. 2  Kaplan–Meier combined 
endpoint of all-cause mortality 
and heart failure hospitalization 
for loop diuretic dosing (low vs. 
high: > 80 mg of furosemide)
 Clinical Research in Cardiology
1 3
In contrast, we did not find an association between higher 
loop diuretic doses and uptitration of MRAs and beta-block-
ers. A possible explanation for the lack of association with 
MRA uptitration is that patients with higher doses of loop 
diuretics at baseline have more severe heart failure and as 
such more frequently already used MRAs. Furthermore, 
MRAs are often initiated at target dose; therefore, uptitra-
tion is not pursued in clinical practice. Finally, the lack of 
an association between loop diuretic doses and beta-blocker 
uptitration might be the result that triggers to limit upti-
tration of beta-blockers, such as a low heart rate, are not 
similarly influence by loop diuretic dose, as triggers to limit 
uptitration of ACEi/ARB (e.g., worsening of renal function 
and hypotension).
An additional important finding of the present study was 
that patients with a decrease in signs and symptoms of con-
gestion but residual high doses of loop diuretics were less 
likely to receive uptitration with ACEi/ARB. Moreover, 
the doses these patients eventually attained were actually 
lower than doses observed in patients with persistent con-
gestion, yet with lower doses of loop diuretics. The higher 
doses of loop diuretics in the group with an improvement 
of congestion could indicate a phenotype requiring higher 
doses to maintain euvolemia and as such more severe heart 
failure, precluding uptitration of neurohormonal blockers. 
Yet, it could also be hypothesized that these patients could 
not be uptitrated due to the high doses of loop diuretics, 
which may not have been necessary based on the conges-
tion status of the patient. Unfortunately, due to the small 
groups of patients with this data available, further analysis 
was not able to shed more light on this. Nevertheless, based 
on our findings and the consensus from a recent position 
paper, we would advise attempting loop diuretic downtitra-
tion in patients without any residual signs and symptoms of 
congestion (i.e., euvolemic patients), to facilitate successful 
uptitration of neurohormonal blockers [20].
Loop diuretics and outcome
Several studies have shown an association between higher 
doses of loop diuretics and poor outcome [4, 21]. Our study 
corroborates the previous findings of an association between 
higher loop diuretic dose and adverse clinical outcome. The 
finding that loop diuretic downtitration was not associated 
with improved outcome might be related to the fact that loop 
diuretic downtitration was particularly possible in patients 
treated at baseline with higher doses. This might indicate a 
selection bias towards a sicker patient population, preclud-
ing a detection of a beneficial effect of loop diuretic down-
titration. Another explanation could be that physicians are 
generally very good in identifying patients in which diuretics 
can be downtitrated or even withheld, which is in line with 
previous findings by Martens et al. [7].
We found a significant association between higher 
loop diuretic dosage and worsening renal function, which 
remained statistically significant after propensity adjustment, 
and was independent of baseline renal function. This detri-
mental effect of loop diuretics on worsening renal function 
is, perhaps, directly related to the pharmacology of loop diu-
retics, since renal blood flow is decreased by loop diuretics 
through the so-called tubuloglomerular feedback.
Fig. 3  Kaplan–Meier combined 
endpoint of all-cause mortality 
and heart failure hospitalization 
for baseline loop diuretic dosing 
and > 50% of target dose of 
ACEi/ARB at 3 months. ACEi/
ARB angiotensin-converting 
enzyme inhibitors/angiotensin 
receptor blockers, HD high-dose 
loop diuretics, LD low-dose 
loop diuretics
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Strengths and limitations
This is the first study to assess the effect of loop diuretic 
dosage on uptitration of doses of ACEi/ARB. Strengths of 
the study are the design of the BIOSTAT-CHF trial, making 
it a suitable cohort to assess this research question, as well 
as the number of patients enrolled in different European cen-
tres. Limitations are the retrospective, observational design, 
making it impossible to prove causality, and merely allows 
us to describe associations. Furthermore, propensity score 
adjustment is in our opinion the best approach to correct 
for treatment selection bias in prescribing higher doses of 
loop diuretic dosage; however, we cannot exclude residual 
confounding. Uptitration was encouraged, yet not forced 
and left to the discretion of the treating physician. Reasons 
for not uptitrating guideline-recommended therapies were 
carefully collected, yet unfortunately often specified as 
“other”. Reasons for changes in doses of diuretics were not 
collected. Diuretic doses were relatively low at the start of 
the study and were only available at time of enrolment and 
at 9 months. Changes in the meantime, such as during the 
index hospitalization, were not captured. Signs and symp-
toms of congestion at 9 months were only available in 49.9% 
of patients alive at 9 months. Additionally, a limited number 
of echocardiographic parameters were available, which did 
not include right-ventricular function or specific assessments 
of valve dysfunction. Finally, even though uptitration was 
encouraged, the number of patients in BIOSTAT-CHF that 
achieved target doses of ACEi/ARB was limited [22].
Conclusions
In patients with HFrEF, higher doses of loop diuretics are 
associated with poorer uptitration of ACEi/ARB and with 
a higher risk of death and/or heart failure hospitalization, 
independent of the lower likelihood of uptitration and higher 
baseline risk.
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